224 related articles for article (PubMed ID: 35365418)
1. Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease.
Huh JH; Kim KJ; Kim SU; Cha BS; Lee BW
Hepatobiliary Pancreat Dis Int; 2022 Jun; 21(3):241-247. PubMed ID: 35365418
[TBL] [Abstract][Full Text] [Related]
2. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status.
Huh JH; Kim KJ; Kim SU; Han SH; Han KH; Cha BS; Chung CH; Lee BW
Metabolism; 2017 Jan; 66():23-31. PubMed ID: 27923446
[TBL] [Abstract][Full Text] [Related]
3. High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease.
Zhu C; Huang D; Ma H; Qian C; You H; Bu L; Qu S
Front Endocrinol (Lausanne); 2022; 13():848937. PubMed ID: 35620390
[TBL] [Abstract][Full Text] [Related]
4. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
[TBL] [Abstract][Full Text] [Related]
5. Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease.
Lee CH; Lui DT; Li RH; Yuen MM; Fong CH; Leung AP; Chu JC; Mak LL; Lam TH; Woo J; Woo YC; Xu A; Tse HF; Tan KC; Cheung BM; Yuen MF; Lam KS
Front Endocrinol (Lausanne); 2022; 13():1056562. PubMed ID: 36686469
[TBL] [Abstract][Full Text] [Related]
6. Simple proxies of insulin resistance identify obese metabolic dysfunction-associated fatty liver disease subjects with advanced liver disease.
Petralli G; Salvati A; Tricò D; Ricco G; Colombatto P; Brunetto MR; Solini A
Diabetes Metab Res Rev; 2024 Feb; 40(2):e3736. PubMed ID: 37839068
[TBL] [Abstract][Full Text] [Related]
7. Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Hepatol Commun; 2022 Aug; 6(8):2070-2078. PubMed ID: 35470984
[TBL] [Abstract][Full Text] [Related]
8. Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy.
Park H; Yoon EL; Kim M; Cho S; Nah EH; Jun DW
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1041-1049.e3. PubMed ID: 35504562
[TBL] [Abstract][Full Text] [Related]
9. The association of triglyceride-glucose-waist circumference with metabolic associated fatty liver disease and the severity of liver steatosis and fibrosis in American adults: a population-based study.
Wu Z; Huang K; Bao S; Zhang X; Li J; Kong W; Shi Y; Xie Y
Scand J Gastroenterol; 2024 May; 59(5):561-569. PubMed ID: 38235548
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
Avcu A; Kaya E; Yilmaz Y
Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis.
Kwon YD; Ko KO; Lim JW; Cheon EJ; Song YH; Yoon JM
J Korean Med Sci; 2019 Jun; 34(23):e165. PubMed ID: 31197983
[TBL] [Abstract][Full Text] [Related]
12. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
[TBL] [Abstract][Full Text] [Related]
13. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
[TBL] [Abstract][Full Text] [Related]
14. Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease.
Sohn W; Kwon HJ; Chang Y; Ryu S; Cho YK
Clin Gastroenterol Hepatol; 2022 May; 20(5):e1135-e1148. PubMed ID: 34224877
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
[TBL] [Abstract][Full Text] [Related]
16. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
[TBL] [Abstract][Full Text] [Related]
17. Higher dietary insulinaemic potential is associated with increased risk of liver steatosis and fibrosis.
Zhu Y; Peng Z; Lu Y; Li H; Zeng X; Zhang Z; Li X; Hu C; Hu A; Zhao Q; Wang H; Yang W
Liver Int; 2022 Jan; 42(1):69-79. PubMed ID: 34521152
[TBL] [Abstract][Full Text] [Related]
18. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
20. Identification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity.
Barranco-Fragoso B; Pal SC; Díaz-Orozco LE; Dorantes-Heredia R; Qi X; Méndez-Sánchez N
Med Sci Monit; 2022 Aug; 28():e937528. PubMed ID: 35934868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
